CJC-1295/Ipamorelin Research Overview (also known as Pulsatile Growth Hormone Optimization)
A combination protocol using CJC-1295 without DAC (also known as Mod GRF 1-29) and Ipamorelin through complementary receptor mechanisms. CJC-1295 without DAC has a short half-life of 30 minutes to 2 hours, enabling pulsatile GH release that mimics natural physiology. Ipamorelin provides selective GH release without affecting cortisol, ACTH, or prolactin. Note: This protocol uses the no-DAC version specifically for pulsatile release patterns.
What Is CJC-1295/Ipamorelin?
A combination protocol using CJC-1295 without DAC (also known as Mod GRF 1-29) and Ipamorelin through complementary receptor mechanisms. CJC-1295 without DAC has a short half-life of 30 minutes to 2 hours, enabling pulsatile GH release that mimics natural physiology. Ipamorelin provides selective GH release without affecting cortisol, ACTH, or prolactin. Note: This protocol uses the no-DAC version specifically for pulsatile release patterns.
Key Benefits
- Synergistic dual-pathway stimulation — CJC-1295 activates GHRH receptors while Ipamorelin activates ghrelin receptors, amplifying GH release 2–3x over either peptide alone
- Clean, selective GH pulse — Ipamorelin does not raise cortisol, ACTH, or prolactin at research doses
- Pulsatile release pattern mimics natural physiology, reducing receptor desensitization versus continuous GH elevation
- Supports body composition, recovery, sleep quality, and longevity across multiple published studies
- Among the best-tolerated GH secretagogue combinations with a well-characterized safety profile
Mechanism of Action
CJC-1295 (no DAC / Mod GRF 1-29) binds GHRH receptors on pituitary somatotrophs, driving cAMP production and GH synthesis. Its short half-life (30 min–2 hrs) due to DPP-IV cleavage produces a sharp pulse rather than sustained elevation. Ipamorelin selectively activates the ghrelin receptor (GHS-R1a) via a distinct PKC/IP3 pathway, amplifying GH release without affecting cortisol, ACTH, or prolactin. The two peptides act on separate receptors simultaneously, producing a robust, clean GH surge that normalizes within 2–3 hours and preserves receptor sensitivity over repeated cycles.
Research Indications
Muscle Growth & Body Composition
GH-driven IGF-1 synthesis supports muscle protein synthesis, nitrogen retention, and lean mass gains — especially effective when combined with resistance training.
Anti-Aging & Longevity
GH secretion declines ~14% per decade after age 30. This combination supports restoration of youthful GH pulsatility, improving skin quality, energy, and metabolic markers.
Recovery & Tissue Repair
Elevated GH accelerates connective tissue and muscle recovery between training sessions, reduces DOMS severity, and supports collagen synthesis.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| General health optimization | 200 mcg each peptide | Once daily before bed | SubQ |
| Enhanced GH pulsatility | 100–150 mcg each peptide | Twice daily (AM + before bed) | SubQ |
| Performance enhancement | 250–300 mcg each peptide | Once daily before bed | SubQ |
| Conservative approach | 150 mcg each peptide | 5 days per week | SubQ |
Timing
Inject 30–60 minutes before bed in a fasted state (2–3 hour fast prior). For twice-daily dosing the morning injection should also be fasted — at least 2–3 hours since last calories. CJC-1295 without DAC has a half-life of approximately 30 minutes to 2 hours; this enables pulsatile GH release and is NOT interchangeable with the DAC version (8-day half-life). Cycle 8–12 weeks on with at least 4 weeks off.
Peptide Interactions
Both affect GH pathways. Monitor for excessive GH elevation and potential insulin sensitivity changes with combined use.
No known interactions. Different mechanisms - GH optimization versus direct tissue repair signaling.
Growth hormone affects insulin sensitivity. Diabetic users require blood glucose monitoring and potential insulin dose adjustments.
Redundant mechanisms may cause excessive GH levels and suppress natural pulsatile release patterns.
Space thyroid medications 4+ hours from GH secretagogues due to potential absorption and metabolic interactions.
Corticosteroids can blunt GH response. May require higher doses or alternative timing when used together.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Administer in a fasted state — food significantly blunts GH release; fast 2–3 hours before injection
Monitor blood glucose levels; GH elevation can temporarily affect insulin sensitivity at higher doses
Cycle off 4 weeks minimum after every 8–12 week run to preserve GHS-R1a receptor sensitivity
Not recommended during pregnancy, breastfeeding, or active cancer
Use pharmaceutical-grade peptides with verified CoA from reputable vendors
Seek Medical Attention If:
Unusual swelling or persistent injection site reactions not resolving within a few days
Significant or unexpected changes in blood glucose or insulin response
Persistent headaches, dizziness, or vision changes
Quality Indicators
Verified
Standard format labeling
Product should clearly identify CJC-1295 without DAC (Mod GRF 1-29) and Ipamorelin separately. Separate vials allow individual dose adjustment.
CAUTION — NOT RECOMMENDED
DAC version mislabeling
Ensure "no DAC" is specified. The DAC version has an 8-day half-life and is NOT interchangeable with this protocol.
Verified
1:1 ratio confirmation
Equal amounts of each peptide are recommended for optimal complementary effects.
Verified
Clear reconstitution
Solution should dissolve completely clear without particles or cloudiness. Discard if cloudy or particulate.
Verified
Certificate of Analysis
Quality vendors provide CoA showing purity of 98% or more by HPLC for both peptides with confirmed amino acid sequence.
Caution
Research limitations
Combination protocols extrapolate from individual peptide studies. Direct clinical validation of the blend is limited — titrate doses conservatively.
Reported Research Timeline
01Week 1–2 (reported in cited studies): improved sleep depth and quality; vivid dreams reported by many subjects; initial GH pulse signaling begins.
02Week 3–4 (reported in cited studies): reduced muscle soreness and faster recovery from training; increased morning energy levels.
03Week 8–12 (reported in cited studies): gradual body composition improvements — improved muscle quality and reduced fat accumulation with consistent training and diet.
04Post-cycle: Sleep quality and recovery improvements often persist beyond the cycle. After a 4-week break, repeat cycles typically show consistent results.
Research Citations
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman, S.L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J.P., & Frohman, L.A., 2006, Journal of Clinical Endocrinology & Metabolism - Ipamorelin, the first selective growth hormone secretagogue
Raun, K., Hansen, B.S., Johansen, N.L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P.H., 1998, European Journal of Endocrinology - Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295
Ionescu, M. & Frohman, L.A., 2006, Journal of Clinical Endocrinology & Metabolism - Ghrelin and growth hormone secretagogues potentiate GHRH-induced cAMP production
Cunha, S.R., & Mayo, K.E., 2002, Endocrinology - Molecular recognition of an acyl-peptide hormone and activation of ghrelin receptor
Wang, X., Qin, C., Zhao, L.H., et al., 2021, Nature Communications - Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers
Gobburu, J.V.S., Agersø, H., Jusko, W.J., & Ynddal, L., 1999, Pharmaceutical Research - Desensitization and endocytosis mechanisms of ghrelin-activated growth hormone secretagogue receptor 1a
Camiña, J.P., Carreira, M.C., El Messari, S., Llorens-Cortes, C., Smith, R.G., & Bhattacharya, S., 2004, Endocrinology - The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
Dominikowski A, Rękoś Z, Olejarz M, 2026, Front Endocrinol (Lausanne)
"
Verified Vendors Carrying CJC-1295/Ipamorelin
Frequently Asked Questions
What should researchers watch for with CJC-1295/Ipamorelin?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with CJC-1295/Ipamorelin?
Week 1–2 (reported in cited studies): improved sleep depth and quality; vivid dreams reported by many subjects; initial GH pulse signaling begins.
How is CJC-1295/Ipamorelin typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →